Navigation Links
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Date:10/27/2008

cating that the early increase in flares was transient

in this treatment arm before returning to the placebo level.

The reduction of gout flares, by approximately 40%, in the every two-

week dosing arm of these randomized, controlled, clinical trials is

believed to be the first time a urate lowering therapy has demonstrated

a reduction of gout flares versus a placebo.

New results presented from the GOUT 3 study show that for patients who

have been treated with pegloticase continuously for at least 12

months, the frequency of gout flares was reduced to approximately 0.2

flares per three months in the pegloticase every two weeks group, and

0.4 flares per 3 months in the every four weeks group. This represents

a 9-fold and 4-fold reduction in the frequency of gout flares after 12

months of continuous therapy for the every two and every four weeks

groups compared to the flare frequency reported prior to study entry.

Patients and their physicians participating in GOUT 3 study view this

reduction in gout flare frequency as an important clinical benefit and

the Company believes this benefit contributes to their joint decision

to continue therapy.

-- Immunology: The Company previously reported on the immune response to

pegloticase treatment in the GOUT 1 and GOUT 2 studies, showing a high

rate of seroconversion. The presence of anti-pegloticase antibodies

was predictive of a loss of uric acid control and a greater increase in

the risk of infusion reactions, but not a greater severity of infusion

reactions, particularly in the subset of patients with the highest one-

third of antibody titer.

Results of the GOUT 3 study reported confirm that for patients treated

with pegloticase for up to 12 months showed that:

- The overwhelming m
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
2. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
3. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
9. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
10. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
11. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... global market for molecular diagnostics is expected to reach ... study by Grand View Research, Inc. Growing demand for ... advanced cancer diagnostic technologies are expected to be key ... Moreover, the growing global base of geriatric population and ... lifestyle habits such as smoking and excessive alcohol consumption ...
(Date:7/31/2014)... 31, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues, today ... results will be released on Thursday, August 7, 2014, ... and live webcast at 4:30 p.m. ET that afternoon. ...
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... NYSE: SNY) today announced that the Companies intend to ... pediatric disease priority review voucher in connection with the ... review voucher entitles the holder to designate a BLA ... review from the filing date instead of the standard ...
Breaking Biology Technology:Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... of GE Healthcare in Milwaukee, has built the ... , ,The MRI, which is used to study internal anatomy ... magnet. A tesla is a unit of magnetic strength. The ... times the strength of the Earths magnetic field. , ,While ...
... Source: Wisconsin Paper Council APPLETON, Wis. Foreign ... the latest technology and find new marketsor slowly perish. ... a story from 1911. It still serves as an ... newsprint producer in the United States. That dominance faded ...
... serious fight between Apple Computers and Apple Records (of Beatles fame) ... of the ring is Sir Paul McCartney, with the title of ... On the other side, yet another youthful boy wonder, Steve Jobs ... to lead the start of the personal computer revolution. , ,The ...
Cached Biology Technology:Wisconsin's paper industry needs technology, innovation to prosper. 2Wisconsin's paper industry needs technology, innovation to prosper. 3Why you should never name your company after a fruit 2Why you should never name your company after a fruit 3
(Date:7/31/2014)... hazard lurks beneath many of the roughly 156,000 ... hazard is corrosion in parts of underground gas ... and contamination of groundwater, a source of drinking ... states have reported many rapidly corroding gas storage ... are generally associated with use of gasoline-ethanol blends ...
(Date:7/31/2014)... available in German . ... gases similar to a sponge that soaks up liquids. ... hydrogen or greenhouse gases. However, loading of many MOFs ... Technology (KIT) now report in Nature Communications ... MOF surface. This can be prevented by water-free synthesis ...
(Date:7/31/2014)... alters how the brain processes speech, potentially increasing ... neuroscientists at The University of Texas at Dallas. ... Ear and Hearing , researchers demonstrated for ... the brain,s recognition of speech sounds. , Noise-induced ... population, affecting an estimated 15 percent of Americans ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2Free pores for molecule transport 2UT Dallas study reveals effect of loud noises on brain 2
... focus on forestsas opposed to the entire landscapecould ... poor in developing countries, said a Nairobi-based agroforestry ... forest degradation is driven by forces outside forests, ... land uses that involve the whole landscape, not ...
... This release is available in French . ... Laval, in collaboration with Nova Scotia Agricultural College, have discovered ... to double the lifespan of Christmas trees in homes. The ... scientific journal Trees . The researchers have identified ...
... Personality is not just a feature unique to humans ... have revealed that also brown trout have individual characters ... the Department of Zoology at the University of Gothenburg ... trout from watercourses on the west coast of Sweden. ...
Cached Biology News:Towards an efficient, effective and equitable REDD+ 2Towards an efficient, effective and equitable REDD+ 3Towards an efficient, effective and equitable REDD+ 4Researchers discover a way to delay Christmas tree needle loss 2
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
... cytoplasmic expression of an N-terminal FLAG® fusion ... selection marker from bicistronic mRNA. Two ... MCS2 for transcription of a single message ... useful for protein-protein interaction studies, multi-subunit proteins, ...
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
Biology Products: